Remdesivir magani ne na rigakafi wanda ke kaiwa nau'ikan ƙwayoyin cuta. An samo asali ne sama da shekaru goma da suka wuce don magance cutar hanta ta C da kuma kwayar cutar sanyi mai suna numfashi syncytial virus (RSV). Remdesivir ba magani mai inganci ba ne ga kowace cuta. Amma ya nuna alkawari a kan sauran ƙwayoyin cuta.

Masu bincike sun gwada remdesivir a gwajin asibiti lokacin barkewar cutar Ebola. Sauran magungunan bincike sun yi aiki mafi kyau, amma an nuna cewa yana da lafiya ga marasa lafiya. Nazarin a cikin sel da dabbobi sun nuna cewa remdesivir yana da tasiri a kan ƙwayoyin cuta a cikin dangin coronavirus, kamar Ciwon Ciwon Gabas ta Tsakiya (MERS) da Ciwon Cutar Cutar Cutar Cutar Cutar (SARS).

Remdesivir yana aiki ta hanyar katse samar da kwayar cutar. Coronaviruses suna da kwayoyin halittar da aka yi da ribonucleic acid (RNA). Remdesivir yana tsoma baki tare da ɗaya daga cikin mahimman enzymes da ƙwayar cuta ke buƙatar yin kwafin RNA. Wannan yana hana ƙwayar cuta yaduwa.

Masu bincike sun fara gwajin bazuwar, gwajin sarrafa ƙwayar cuta a cikin Fabrairu 2020 don gwada ko za a iya amfani da remdesivir don kula da SARS-CoV-2, coronavirus da ke haifar da COVID-19. A watan Afrilu,sakamakon farkoya nuna cewa remdesivir yana hanzarta murmurewa ga marasa lafiya da ke asibiti tare da COVID-19 mai tsanani. Ya zama magani na farko da ya karɓi izinin amfani da gaggawa daga Hukumar Abinci da Magunguna ta Amurka (FDA) don kula da mutanen da ke asibiti tare da COVID-19.

Masu bincike yanzu sun kammala gwajin, wanda aka sani da Gwajin Jiyya na Adabi na COVID-19 (ACTT-1). Cibiyar Nazarin Allergy da Cututtuka (NIAID) ce ta dauki nauyin binciken. Rahoton karshe ya bayyana a cikinNew England Journal of Medicinea ranar Oktoba 2020.